Adverse reactions of prophylactic intravenous immunoglobulin: A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 2, 2009, Pages 139-145

  Dashti Khavidaki, S ^a   Aghamohammadi, A ^a,c   Farshadi, F ^a   Movahedi, M ^a   Parvaneh, N ^a   Pouladi, N ^a   Moazzami, K ^a   Cheraghi, T ^a   Mahdaviani, S A ^a   Saghafi, S ^a   Heydari, G ^a   Abdollahzade, S ^a   Rezaei, N ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse reactions; Infusion; Intravenous immunoglobulin; Primary antibody deficiencies; Primary immunodeficiency diseases

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; IG VENA NIV; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; INTRAGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIMMUN; UNCLASSIFIED DRUG; VIGAM;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADOLESCENT; ADULT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; ATAXIA TELANGIECTASIA; BACKACHE; BRONCHOSPASM; CHILD; CHILL; COLD FEELING; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLUSHING; GROUPS BY AGE; HEADACHE; HUMAN; HYPER IGM SYNDROME; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOPROPHYLAXIS; INFECTION; IRAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; PRESCHOOL CHILD; PRURITUS; SCHOOL CHILD; SIDE EFFECT; THERAPY DELAY; THORAX PAIN; URTICARIA; VOMITING; WHEEZING; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DRUG COMPOUNDING; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFUSIONS, INTRAVENOUS; IRAN; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; QUALITY OF LIFE;

EID: 65249158516     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chapel H, Geha R, Rosen F. Primary Immunodeficiency diseases: an update. Clin Exp Immunol. 2003;132:9-15.
2. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325:1 10-7.
3. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, Gharagozlou M, Nabavi M, Shahrokhi A. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40:113-8.
4. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI, Le Deist F, de Saint Basile G, Fischer A. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134:589-96.
5. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109:1001-4.
6. Bayrakci B, Ersoy F, Sanal O, Kilic S, Metin A, Tezcan I. The efficacy of immunoglobulin replacement therapy in the long- term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr. 2005;47:239-46.
7. Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:1 14-20.
8. Hedderich U, Kratzsch G, Stephen W, Dichtelmuller H, Olischlager K, Heimpel H. Immunoglobulin substitution therapy in a patient with primary hypogammaglobulinaemia and anti- IgA antibodies. Clin Allergy. 1986;16:339-44.
9. Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92:200-4.
10. Atarod L, Aghamohammadi A, Moin M, Kanegane H, Rezaei N, Rezaei Kalantari K, Amirzagar AA, Futatani T, Miyawaki M. Successful management of neutropenia in a patient with CD40 ligand deficiency by immunoglobulin replacement therapy. Iran J Allergy Asthma Immunol. 2007;6:37-40.
11. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc (Wash). 2002;42:449-58; quiz 58-9.
12. Fasano MB. Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opin Pediatr. 1995;7:688-94.
13. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. 1996;74:527-30.
14. Brennan VM, Cochrane S, Fletcher C, Hendy D, Powell P. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol. 1995;15:116-9.
15. Pautard B, Hachulla E, Bagot d'Arc M, Chantreuil L. [Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children]. Rev Med Interne. 2003;24:505-13.
16. Al-Wahadneh AM, Khriesat IA, Kuda EH. Adverse reactions of intravenous immunoglobulin. Saudi Med J. 2000;21:953-6.
17. Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl- Roth K, Urban C. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol. 2003;25:797-800.
18. Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol. 1994;97 Suppl 1:11-5.
19. Aghamohammadi A, Moein M, Farhoudi A, Pourpak Z, Rezaei N, Abolmaali K, Movahedi M, Gharagozlou M, Ghazi BM, Mahmoudi M, Mansouri D, Arshi S, Trash NJ, Akbari H, Sherkat R, Hosayni RF, Hashemzadeh A, Mohammadzadeh I, Amin R, Kashef S, Alborzi A, Karimi A, Khazaei H. Primary immunodeficiency in Iran: first report of the National Registry of PID in Children and Adults. J Clin Immunol. 2002;22:375-80.
20. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, Atarod L, Ghazi BM, Isaeian A, Mahmoudi M, Abolmaali K, Mansouri D, Arshi S, Tarash NJ, Sherkat R, Akbari H, Amin R, Alborzi A, Kashef S, Farid R, Mohammadzadeh I, Shabestari MS, Nabavi M, Farhoudi A. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26:519-32.
21. Primary immunodeficiency diseases. Report of a WHO scientific group. Clin Exp Immunol. 1997;109 Suppl 1:1-28.
22. Aghamohammadi A, Farhoudi A, Moin M, Rezaei N, Kouhi A, Pourpak Z, Yaseri N, Movahedi M, Gharagozlou M, Zandieh F, Yazadni F, Arshi S, Mohammadzadeh I, Ghazi BM, Mahmoudi M, Tahaei S, Isaeian A. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol. 2005;12:825-32.
23. Aghamohammadi A, Fiorini M, Moin M, Parvaneh N, Teimourian S, Yeganeh M, Goffi F, Kanegane H, Amirzargar AA, Pourpak Z, Rezaei N, Salavati A, Pouladi N, Abdollahzade S, Notarangelo LD, Miyawaki T, Plebani A. Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allergy Immunol. 2006;141:408-14.
24. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. BMJ. 1994;308:581-5.
25. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1:1075-7.
26. Bjorkander J, Wadsworth C, Hanson LA. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection. 1985;13:102-10.
27. Lee YC, Woodfield DG, Douglas R. Clinical usage of intravenous immunoglobulins in Auckland. N Z Med J. 1998;111:48-50.
28. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody- deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247-51.
29. Aghamohammadi A, Farhoudi A, Nikzad M, Moin M, Pourpak Z, Rezaei N, Gharagozlou M, Movahedi M, Atarod L, Afshar AA, Bazargan N, Hosseinpoor AR. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol. 2004;92:60-4.
30. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders- a prospective study. J Neurol. 2003;250:818-21.
31. Galli E, Barbieri C, Cantani A, Solano A, Longhi MA, Businco L. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up. Ann Allergy. 1990;64:147-50.
32. Andres E, Limbach FX, Kurtz JE, Kurtz-Illig V, Schaeverbeke T, Pflumio F, Kuntz JL, Sibilia J. Primary humoral immunodeficiency (late-onset common variable immunodeficiency) with antinuclear antibodies and selective immunoglobulin deficiency. Am J Med. 2001;111:489-91.
33. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48.
34. Eisenstein EM, Sneller MC. Common variable immunodeficiency: diagnosis and management. Ann Allergy. 1994;73:285-92; quiz 93-4.
35. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol. 2000;20:77-82.
36. Day NK, Good RA, Wahn V. Adverse reactions in selected patients following intravenous infusions of gamma globulin. Am J Med. 1984;76:25-32.
37. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang. 1998;74:74-82.
38. IDF. Immune Deficiency Foundation patient survey. Available from: http://www.primaryimmune.org; 2002.
39. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Jr., Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham- Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525-53.
40. Gelfand EW, Winkelstein J. Are all IGIVs the same? J Allergy Clin Immunol. 2002;110:938.
41. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136:111-3.